STAG2 and acute myeloid leukemia: In a recent study of 86 patients treated at the Memorial Sloan Kettering Cancer Center (New York, NY, USA), a novel association between STAG2 mutations and improved survival after azacitidine–venetoclax combination was reported, albeit only when azacitidine–venetoclax was administered for relapsed/refractory AML [96].